O	0	4	Gene	Gene	NN	B-NP
O	5	12	therapy	therapy	NN	I-NP
O	13	16	for	for	IN	B-PP
B-Cancer	17	24	gliomas	glioma	NNS	B-NP
O	24	25	:	:	:	O
O	26	29	p53	p53	NN	B-NP
O	30	33	and	and	CC	I-NP
O	34	37	E2F	E2F	NN	I-NP
O	37	38	-	-	HYPH	B-NP
O	38	39	1	1	CD	I-NP
O	40	48	proteins	protein	NNS	I-NP
O	49	52	and	and	CC	O
O	53	56	the	the	DT	B-NP
O	57	63	target	target	NN	I-NP
O	64	66	of	of	IN	B-PP
O	67	76	apoptosis	apoptosis	NN	B-NP
O	76	77	.	.	.	O

O	79	86	Current	Current	JJ	B-NP
O	87	94	therapy	therapy	NN	I-NP
O	95	98	for	for	IN	B-PP
B-Cancer	99	105	glioma	glioma	NN	B-NP
O	106	108	is	be	VBZ	B-VP
O	109	119	suboptimal	suboptimal	JJ	B-ADJP
O	119	120	.	.	.	O

O	121	124	The	The	DT	B-NP
O	125	133	transfer	transfer	NN	I-NP
O	134	136	of	of	IN	B-PP
O	137	146	apoptosis	apoptosis	NN	B-NP
O	147	152	genes	gene	NNS	I-NP
O	153	155	to	to	TO	B-PP
B-Cancer	156	162	tumors	tumor	NNS	B-NP
O	163	174	constitutes	constitute	VBZ	B-VP
O	175	178	one	one	CD	B-NP
O	179	181	of	of	IN	B-PP
O	182	185	the	the	DT	B-NP
O	186	190	most	most	RBS	I-NP
O	191	200	promising	promising	JJ	I-NP
O	201	211	strategies	strategy	NNS	I-NP
O	212	215	for	for	IN	B-PP
B-Cancer	216	222	cancer	cancer	NN	B-NP
O	223	227	gene	gene	NN	I-NP
O	228	235	therapy	therapy	NN	I-NP
O	235	236	.	.	.	O

O	237	239	We	We	PRP	B-NP
O	240	244	have	have	VBP	B-VP
O	245	255	previously	previously	RB	I-VP
O	256	261	shown	show	VBN	I-VP
O	262	266	that	that	IN	B-SBAR
O	267	274	massive	massive	JJ	B-NP
O	275	284	apoptosis	apoptosis	NN	I-NP
O	285	291	occurs	occur	VBZ	B-VP
O	292	296	when	when	WRB	B-ADVP
O	297	301	wild	wild	JJ	B-NP
O	301	302	-	-	HYPH	I-NP
O	302	306	type	type	NN	I-NP
O	307	310	p53	p53	NN	I-NP
O	311	313	or	or	CC	I-NP
O	314	317	E2F	E2F	NN	I-NP
O	317	318	-	-	HYPH	O
O	318	319	1	1	CD	B-NP
O	320	330	expression	expression	NN	I-NP
O	331	333	is	be	VBZ	B-VP
O	334	341	induced	induce	VBN	I-VP
O	342	344	in	in	IN	B-PP
B-Cancer	345	351	glioma	glioma	NN	B-NP
O	351	352	.	.	.	O

O	353	360	However	However	RB	B-ADVP
O	360	361	,	,	,	O
O	362	365	the	the	DT	B-NP
O	366	375	mechanism	mechanism	NN	I-NP
O	376	378	of	of	IN	B-PP
O	379	385	action	action	NN	B-NP
O	386	389	and	and	CC	O
O	390	393	the	the	DT	B-NP
O	394	404	efficiency	efficiency	NN	I-NP
O	405	407	in	in	IN	B-PP
O	408	416	inducing	induce	VBG	B-VP
O	417	426	apoptosis	apoptosis	NN	B-NP
O	427	429	of	of	IN	B-PP
O	430	435	these	these	DT	B-NP
O	436	439	two	two	CD	I-NP
O	440	448	proteins	protein	NNS	I-NP
O	449	452	are	be	VBP	B-VP
O	453	456	not	not	RB	O
O	457	464	similar	similar	JJ	B-ADJP
O	464	465	.	.	.	O

O	466	476	Adenovirus	Adenovirus	NN	B-NP
O	476	477	-	-	HYPH	B-PP
O	477	485	mediated	mediate	VBN	B-NP
O	486	489	p53	p53	NN	I-NP
O	490	494	gene	gene	NN	I-NP
O	495	503	transfer	transfer	NN	I-NP
O	504	506	is	be	VBZ	B-VP
O	507	518	ineffective	ineffective	JJ	B-ADJP
O	519	521	in	in	IN	B-PP
O	522	529	causing	cause	VBG	B-VP
O	530	539	apoptosis	apoptosis	NN	B-NP
O	540	542	in	in	IN	B-PP
B-Cell	543	549	glioma	glioma	NN	B-NP
I-Cell	550	555	cells	cell	NNS	I-NP
O	556	560	that	that	WDT	B-NP
O	561	567	retain	retain	VBP	B-VP
O	568	572	wild	wild	JJ	B-NP
O	572	573	-	-	HYPH	I-NP
O	573	577	type	type	NN	I-NP
O	578	581	p53	p53	NN	I-NP
O	582	590	genotype	genotype	NN	I-NP
O	591	593	or	or	CC	O
O	594	605	overexpress	overexpres	VBP	B-VP
O	606	609	the	the	DT	B-NP
O	610	613	p21	p21	NN	I-NP
O	614	621	protein	protein	NN	I-NP
O	621	622	.	.	.	O

O	623	626	The	The	DT	B-NP
O	627	630	p16	p16	NN	I-NP
O	630	631	/	/	SYM	B-VP
O	631	633	Rb	Rb	NN	B-NP
O	633	634	/	/	SYM	I-NP
O	634	637	E2F	E2F	NN	I-NP
O	638	645	pathway	pathway	NN	I-NP
O	646	648	is	be	VBZ	B-VP
O	649	652	the	the	DT	B-NP
O	653	657	most	most	RBS	I-NP
O	658	666	frequent	frequent	JJ	I-NP
O	667	673	target	target	NN	I-NP
O	674	676	of	of	IN	B-PP
O	677	684	genetic	genetic	JJ	B-NP
O	685	696	alterations	alteration	NNS	I-NP
O	697	699	in	in	IN	B-PP
B-Cancer	700	707	gliomas	glioma	NNS	B-NP
O	707	708	,	,	,	O
O	709	712	and	and	CC	O
O	713	722	therefore	therefore	RB	B-VP
O	723	734	constitutes	constitute	VBZ	I-VP
O	735	736	a	a	DT	B-NP
O	737	745	suitable	suitable	JJ	I-NP
O	746	752	target	target	NN	I-NP
O	753	756	for	for	IN	B-PP
O	757	761	gene	gene	NN	B-NP
O	762	769	therapy	therapy	NN	I-NP
O	770	780	strategies	strategy	NNS	I-NP
O	780	781	.	.	.	O

O	782	789	However	However	RB	B-ADVP
O	789	790	,	,	,	O
O	791	794	the	the	DT	B-NP
O	795	803	transfer	transfer	NN	I-NP
O	804	806	of	of	IN	B-PP
O	807	813	either	either	CC	O
O	814	817	the	the	DT	B-NP
O	818	821	p16	p16	NN	I-NP
O	822	824	or	or	CC	I-NP
O	825	827	Rb	Rb	NN	I-NP
O	828	832	gene	gene	NN	I-NP
O	833	835	to	to	TO	B-PP
B-Cell	836	842	glioma	glioma	NN	B-NP
I-Cell	843	848	cells	cell	NNS	I-NP
O	849	856	results	result	VBZ	B-VP
O	857	859	in	in	IN	B-PP
O	860	870	cytostatic	cytostatic	JJ	B-NP
O	871	877	effect	effect	NN	I-NP
O	877	878	.	.	.	O

O	879	882	The	The	DT	B-NP
O	883	886	E2F	E2F	NN	I-NP
O	886	887	-	-	HYPH	B-NP
O	887	888	1	1	CD	I-NP
O	889	896	protein	protein	NN	I-NP
O	897	899	is	be	VBZ	B-VP
O	900	904	able	able	JJ	B-ADJP
O	905	907	to	to	TO	B-VP
O	908	914	induce	induce	VB	I-VP
O	915	926	generalized	generalize	VBN	B-NP
O	927	936	apoptosis	apoptosis	NN	I-NP
O	937	939	in	in	IN	B-PP
B-Cancer	940	947	gliomas	glioma	NNS	B-NP
O	948	961	independently	independently	RB	B-ADVP
O	962	964	of	of	IN	B-PP
O	965	968	the	the	DT	B-NP
O	969	972	p53	p53	NN	I-NP
O	972	973	,	,	,	I-NP
O	974	977	p16	p16	NN	I-NP
O	978	980	or	or	CC	I-NP
O	981	983	Rb	Rb	NN	I-NP
O	984	990	status	status	NN	I-NP
O	990	991	.	.	.	O

O	992	994	In	In	IN	B-PP
O	995	1003	addition	addition	NN	B-NP
O	1003	1004	,	,	,	O
O	1005	1008	p21	p21	NN	B-NP
O	1008	1009	-	-	HYPH	B-NP
O	1010	1012	or	or	CC	I-NP
O	1013	1016	p16	p16	NN	I-NP
O	1016	1017	-	-	HYPH	O
O	1017	1025	mediated	mediate	VBN	B-NP
O	1026	1032	growth	growth	NN	I-NP
O	1033	1039	arrest	arrest	NN	I-NP
O	1040	1043	did	do	VBD	B-VP
O	1044	1047	not	not	RB	I-VP
O	1048	1055	protect	protect	VB	I-VP
B-Cell	1056	1062	glioma	glioma	NN	B-NP
I-Cell	1063	1068	cells	cell	NNS	I-NP
O	1069	1073	from	from	IN	B-PP
O	1074	1077	E2F	E2F	NN	B-NP
O	1077	1078	-	-	HYPH	B-NP
O	1078	1079	1	1	CD	I-NP
O	1079	1080	-	-	HYPH	I-NP
O	1080	1088	mediated	mediate	VBN	I-NP
O	1089	1098	apoptosis	apoptosis	NN	I-NP
O	1098	1099	.	.	.	O

O	1100	1103	The	The	DT	B-NP
O	1104	1113	apoptotic	apoptotic	JJ	I-NP
O	1114	1122	molecule	molecule	NN	I-NP
O	1123	1126	bax	bax	NN	I-NP
O	1127	1129	is	be	VBZ	B-VP
O	1130	1137	induced	induce	VBN	I-VP
O	1138	1140	in	in	IN	B-PP
O	1141	1144	p53	p53	NN	B-NP
O	1144	1145	-	-	HYPH	B-NP
O	1145	1153	mediated	mediate	VBN	I-NP
O	1154	1163	apoptosis	apoptosis	NN	I-NP
O	1163	1164	,	,	,	O
O	1165	1168	but	but	CC	O
O	1169	1172	bax	bax	NN	B-NP
O	1173	1175	is	be	VBZ	B-VP
O	1176	1179	not	not	RB	I-VP
O	1180	1187	induced	induce	VBN	I-VP
O	1188	1190	in	in	IN	B-PP
O	1191	1194	E2F	E2F	NN	B-NP
O	1194	1195	-	-	HYPH	B-NP
O	1195	1196	1	1	CD	I-NP
O	1196	1197	-	-	HYPH	I-NP
O	1197	1205	mediated	mediate	VBN	I-NP
O	1206	1215	apoptosis	apoptosis	NN	I-NP
O	1216	1218	in	in	IN	B-PP
B-Cell	1219	1225	glioma	glioma	NN	B-NP
I-Cell	1226	1231	cells	cell	NNS	I-NP
O	1231	1232	.	.	.	O

O	1233	1240	Careful	Careful	JJ	B-NP
O	1241	1250	selection	selection	NN	I-NP
O	1251	1253	of	of	IN	B-PP
O	1254	1262	patients	patient	NNS	B-NP
O	1263	1266	may	may	MD	B-VP
O	1267	1269	be	be	VB	I-VP
O	1270	1279	necessary	necessary	JJ	B-ADJP
O	1280	1286	before	before	IN	B-PP
O	1287	1296	designing	design	VBG	B-VP
O	1297	1308	therapeutic	therapeutic	JJ	B-NP
O	1309	1319	strategies	strategy	NNS	I-NP
O	1320	1325	using	use	VBG	B-VP
O	1326	1332	either	either	CC	O
O	1333	1336	p53	p53	NN	B-NP
O	1337	1339	or	or	CC	I-NP
O	1340	1343	E2F	E2F	NN	I-NP
O	1343	1344	-	-	HYPH	B-NP
O	1344	1345	1	1	CD	I-NP
O	1346	1348	as	as	IN	B-PP
O	1349	1350	a	a	DT	B-NP
O	1351	1362	therapeutic	therapeutic	JJ	I-NP
O	1363	1368	tools	tool	NNS	I-NP
O	1369	1372	for	for	IN	B-PP
B-Cancer	1373	1379	glioma	glioma	NN	B-NP
O	1380	1388	patients	patient	NNS	I-NP
O	1388	1389	.	.	.	O

